CD274 and sarcoma: However, we emphasize that the discordant and not reproducible data regarding PD-L1 expression could be related to the small size of analyzed series and/or the use of different antibodies [134–136].To date, PD-L1 cannot be considered as an effective predictive biomarker to select patients with sarcoma for treatment with ICIs [135].